Measuring and Valuing Outcomes
We have established an excellent reputation for leading innovative, ideas-driven, and theoretically sound research on the measurement and valuation of outcomes. Health care systems should put patient-relevant outcomes at the heart of decisions about funding and providing health and social care.
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.
Two New Papers on EQ-5D-5L Valuation in Ireland
21 August 2018
OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland.
Presentations from EuHEA 2018
2 August 2018
OHE staff recently attended the European Health Economics Association (EuHEA) 2018 conference. In this blog post, we share a selection of our presentations. Establishing a Reasonable…
New Journal Article: Directly Eliciting Personal Utility Functions
31 July 2018
A new article in the European Journal of Health Economics describes the ‘personal utility functions’ approach to valuing health
Presentations from AES and PROMs Summer 2018
24 July 2018
OHE staff recently attended AES and PROMs Summer 2018 conferences. In this blog post, we share a selection of our presentations.
Presentations from ISPOR and HTAi 2018
12 July 2018
OHE staff recently attended ISPOR and HTAi international conferences. In this blog post, we share a selection of our presentations.
OHE at EuHEA 2018
10 July 2018
Meet some of the OHE team at the European Health Economics Association (EuHEA) 2018 conference in Maastricht, 11-14 July.
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
3 July 2018
Cancer survival rates have improved dramatically in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such asimmunotherapies. In the economic modelling of such treatments, the question arises of which utilities should be assigned to patients who show a long-term, durable response.
New Paper in Value in Health: Improving the Quality of Time Trade-Off Data
27 June 2018
This paper demonstrates OHE’s expertise in valuing health outcomes, and its contribution to methods for improving the quality of health valuation data.